natgillin/translations-raw huggingface dataset:
Most cases of bleeding events in patients treated with Stivarga were mild to moderate in severity (Grades 1 and 2: 16.9%), most notably epistaxis (7.6%).
Večina krvavitev je bila pri bolnikih, zdravljenih z zdravilom Stivarga, blagih do zmernih (stopnje 1 in 2: 16,9 %), najpogosteje epistaksa (7,6 %).
Most cases were classed as mild or moderate.
Večina primerov je bila blaga ali zmerna.
Most common adverse reactions are nausea/vomiting, bone marrow suppression (neutropenia, thrombocytopenia), injection site reactions, diarrhoea, stomatitis and increase in hepatic transaminases (ALT/AST).
Najbolj pogosti neželeni učinki so slabost/bruhanje, supresija kostnega mozga (nevtropenija, trombocitopenija), reakcije na mestu injiciranja, driska, stomatitis in zvišane vrednosti jetrnih transaminaz (ALT/AST).
Most common adverse reactions leading to treatment discontinuation in patients treated with Praluent were local injection site reactions.
Najpogostejši neželeni učinek, ki je med prejemniki zdravila Praluent povzročil prenehanje zdravljenja, so bile lokalne reakcije na mestu injiciranja.
Most common adverse reactions observed in these pigs are pyrexia, anorexia and in severe cases ataxia and recumbency.
Najpogostejši neželeni učinki pri teh prašičih so povišana telesna temperatura in anoreksija, v hujših primerih pa ataksija in nezmožnost vstajanja (ležanje).
Most common adverse reactions were local injection site reactions, upper respiratory tract signs and symptoms, and pruritus.
Najpogostejši neželeni učinki so bile lokalne reakcije na mestu injiciranja, znaki in simptomi na zgornjih dihalih in srbenje.
Most drug-drug interactions were studied using a dose of 100 mg mirabegron given as oral controlled absorption system (OCAS) tablets.
Večino medsebojnih delovanj med zdravili so raziskali z odmerkom 100 mg mirabegrona v tabletah OCAS (Oral Controlled Absorption System).
Most dyspnoea events were mild or moderate in severity and the median duration of dyspnoea was two hours in patients receiving cangrelor, (see section 4.8).
Večina dogodkov dispneje je bila po resnosti blagih ali zmernih in mediana trajanja dispneje pri bolnikih, ki so prejeli kangrelor, je bila dve uri (glejte poglavje 4.8).
Most epidemiological studies have revealed neither an increased risk of birth defects in infants born to women who used ethinylestradiol-containing COCs prior to pregnancy, nor a teratogenic effect when ethinylestradiol- containing COCs were taken inadvertently during early pregnancy.
Večina epidemioloških študij ni pokazala niti povečanega tveganja za prirojene napake pri dojenčkih žensk, ki so pred nosečnostjo uporabljale KPK z etinilestradiolom, niti teratogenih učinkov pri tistih ženskah, ki so nevede uporabljale KPK z etinilestradiolom na začetku nosečnosti.
Most episodes were mild to moderate and occurred in a dose­dependent fashion.
V večini primerov so bili ti neželeni učinki blagi do zmerni, pojavili pa so se odvisno od odmerka.
Most events were reported at similar rates between Vaniqa and vehicle.
V pojavnosti neželenih učinkov pri uporabi zdravila Vaniqa ali vehikla ni bilo večjih razlik.
Most frequent adverse reactions Blood and lymphatic system disorders
Najpogostejši neželeni učinki Bolezni krvi in limfatičnega sistema
Most frequent reactions were increase in AP (2.7%), AST (2.3%), ALT (2.0%), blood bilirubin (1.6%) and liver function test abnormal (1.5%).
Najpogostejše reakcije so bile povečane vrednosti alkalne fosfataze (2,7 %), aspartat- aminotransferaze (2,3 %), alanin-aminotransferaze (2,0 %), bilirubina v krvi (1,6 %) in nenormalne vrednosti testov jetrne funkcije (1,5 %).
Most frequently reported (≥5%) symptoms associated with an IRR were nausea, fatigue, chills, hypotension, pyrexia, vomiting, dyspnea, flushing, hypertension, headache, tachycardia, dizziness and diarrhoea.
Simptomi, povezani z infuzijsko reakcijo, o katerih so poročali najpogosteje (≥ 5 %), so bili navzea, utrujenost, mrzlica, hipotenzija, zvišana telesna temperatura, bruhanje, dispneja, zardevanje, hipertenzija, glavobol, tahikardija, omotica in diareja.
Most frequently reported adverse reactions in Tasigna clinical studies
Neželeni učinki, o katerih so najpogosteje poročali v kliničnih študijah z zdravilom Tasigna
Most frequently reported were:
Najpogosteje so poročali o:
Most frequently reported:
Najpogosteje opisani:
Most haematologic adverse reactions were reported commonly or very commonly in both indications (Tables 4 and 5); the frequency of grade 3-4 laboratory findings is presented after each table.
Večina hematoloških neželenih reakcij je bila poročana pogosto ali zelo pogosto pri obeh indikacijah (preglednici 4 in 5), za vsako preglednico pa so po pogostosti razvrščeni laboratorijski izidi stopnje 3-4.
Most haematologic adverse reactions were reported commonly or very commonly in both indications (Tables 4 and 5); the frequency of grade 3-4 laboratory findings is presented after each table.
Večina hematoloških neželenih reakcij je bila poročana pogosto ali zelo pogosto pri obeh indikacijah (preglednici 4 in 5); za vsako preglednico so po pogostosti razvrščeni laboratorijski izidi stopnje 3-4.
Most haemorrhagic events, but not all, occurred in patients with grade 3/4 thrombocytopenia.
Največ krvavitev, vendar ne vse, se je pojavilo pri bolnikih s trombocitopenijo 3./4. stopnje.
Most hypersensitivity reactions to asparaginase are observed during subsequent treatment phases (re- induction treatment, delayed intensification).
Največ preobčutljivostnih reakcij na asparaginazo ugotavljajo med poznejšimi fazami zdravljenja (reindukcijsko zdravljenje, odložena intenzifikacija).
Most individual nodules were asymptomatic, did not interfere with study participation and resolved over 4 to 8 weeks.
Večina nodulov je bila asimptomatska, ni vplivala na udeležbo v študiji in je bila razrešena v 4 do 8 tednih.
Most infections were mild to moderate, and subjects responded to an initial course of standard treatment and rarely resulted in discontinuation from dapagliflozin treatment.
Večina okužb je bila blagih do zmernih, preiskovanci so se odzvali na začetno standardno zdravljenje in okužbe so le redko povzročile prekinitev zdravljenja z dapagliflozinom.
Most lice are killed within 7 days.
Večino uši pobije v 7 dneh.
Most minor reactions to insulins at the injection site usually resolve in a few days to a few weeks.
Večina manjših reakcij na insuline na injekcijskem mestu ponavadi mine v nekaj dneh do nekaj tednih.
Most of the above mentioned effects appear to be due to the pharmacological activity of irbesartan (blockade of angiotensin-II--induced inhibition of renin release, with stimulation of the renin-producing cells) and occur also with angiotensin converting enzyme inhibitors.
Večina naštetih učinkov je verjetno posledica farmakološke aktivnosti irbesartana (blokade z angiotenzinom II inducirane inhibicije sproščanja renina in stimulacije celic, v katerih renin nastaja), in se pojavijo tudi med uporabo zaviralcev angiotenzinske konvertaze.
Most of the adverse events below come from two clinical trials (PROAB3001, PROAB3006) involving PI naïve subjects receiving Agenerase 1200mg twice daily.
Večina navedenih neželenih učinkov izhaja iz dveh kliničnih študij (PROAB3001, PROAB3006), ki sta vključevali osebe, ki so prejemale zdravilo Agenerase v odmerku 1200 mg dvakrat dnevno in s PI- ji predhodno še niso bile zdravljene.
Most of the adverse events below come from two clinical trials (PROAB3001, PROAB3006) involving PI naïve subjects receiving Agenerase 1200mg twice daily.
Večina navedenih neželenih učinkov izhaja iz dveh kliničnih študij (PROAB3001, PROAB3006), ki sta vključevali osebe, ki so prejemale zdravilo Agenerase v odmerku 1200 mg dvakrat dnevno in z zaviralci proteaz (PI-ji) predhodno še niso bile zdravljene.
Most of the adverse reactions reported were transient and of mild intensity.
Večina neželenih učinkov o katerih so poročali, je bila prehodnih in blage narave.
Most of the adverse reactions were mild to moderate in intensity.
Večina neželenih učinkov je bila večinoma blaga do zmerna.
Most of the available information is available in patients with some specific histology type of ALK- positive NSCLC (adenocarcinoma) and limited information is available in the other histologies.
Večina razpoložljivih podatkov se nanaša na bolnike s posebnim histološkim tipom ALK-pozitivnega nedrobnoceličnega raka pljuč (adenokarcinoma), za druge histološke tipe pa so na voljo le omejeni podatki.
Most of the cases of aspergillosis were considered to be refractory to prior therapy in both the posaconazole group (88 %) and in the external control group (79 %).
Večino primerov aspergiloze so ocenili za odporne na predhodno terapijo, tako v skupini za posakonazol (88 %) kot v zunanji kontrolni skupini (79 %).
Most of the cases were observed within the first 2 weeks of starting the treatment (see section 4.8).
V večini primerov se je to zgodilo v prvih 2 tednih zdravljenja (glejte poglavje 4.8.).
Most of the changes in laboratory values in the PegIntron/ribavirin clinical trial were mild or moderate.
V kliničnem preskušanju z zdravilom PegIntron/ribavirinom so bile spremembe v laboratorijskih vrednostih večinoma blage do zmerne.
Most of the changes in laboratory values in the ViraferonPeg/ribavirin clinical trial were mild or moderate.
V kliničnem preskušanju z zdravilom ViraferonPeg/ribavirinom so bile spremembe v laboratorijskih vrednostih večinoma blage do zmerne.
Most of the children and adolescents with Crohn’s disease also showed a reduction in symptoms after adding Remicade to their existing treatment.
Pri večini otrok in mladostnikov s Crohnovo boleznijo je bilo opaziti zmanjšanje simptomov po dodajanju zdravila Remicade obstoječemu zdravljenju.
Most of the effects do not last long and disappear of their own accord.
Večina teh učinkov ne traja dolgo in izgine sama od sebe.
Most of the patients had pre-existing cardiovascular risk factors (see section 4.4).
Večina bolnikov je imela že obstoječe srčnožilne dejavnike tveganja (glejte poglavje 4.4).
Most of the patients in whom these events have been observed had pre- existing cardiovascular risk factors (see section 4.8).
Večina bolnikov, pri katerih so take dogodke opažali, je imela v preteklosti srčnožilne dejavnike tveganja (glejte poglavje 4.8).
Most of the patients in whom these events have been reported had pre-existing cardiovascular risk factors.
Večina bolnikov, pri katerih so poročali o teh dogodkih, je imela predhodno prisotne srčno-žilne dejavnike tveganja.
Most of the patients with bleeding events during the treatment reported bruising (65.3%).
Med bolniki s krvavitvami, do katerih je prišlo v času zdravljenja, je večina poročala o podplutbah (65,3 %).
Most of the photosensitivity reactions were of mild severity (grade 1); grade 2 photosensitivity reactions were reported in two patients (0.7%) receiving 12 weeks of treatment.
Večina fotosenzitivnih reakcij je bila blagih (stopnja 1), o fotosenzitivnih reakcijah stopnje 2 so poročali pri dveh bolnikih (0,7%), ki sta prejemala zdravljenje 12 tednov.
Most of the side effects (80%) occurred within 2 hours.
Največ neželenih učinkov (80 %) se je pojavilo v prvih 2 urah.
Most of the side effects are mild and will generally disappear over time.
Večina neželenih učinkov je blagih in navadno s časom izzvenijo.
Most of the side effects are mild to moderate and will generally disappear a few days to a few weeks after treatment.
Neželeni učinki so večinoma blagi do zmerni in običajno izzvenijo nekaj dni do nekaj tednov po uporabi zdravila.
Most of the side effects related with photodynamic therapy are local effects seen as consequence of triggering the Foscan with the laser.
Večina neželenih učinkov, povezanih s fotodinamičnim zdravljenjem, so lokalni učinki, ki so posledica proženja zdravila Foscan z laserjem.
Most of the side effects reported were transient and of mild intensity.
Večina neželenih učinkov o katerih so poročali, je bila prehodna in blage narave.
Most of the side effects were mild to moderate in intensity.
Neželeni učinki so bili večinoma blagi do zmerni.
Most of the studies looked at the results separately in patients whose tumours had wild- type KRAS (one of the types of RAS genes) and patients whose tumours had mutated KRAS.
V večini študij so rezultate za bolnike s tumorji z divjim tipom gena KRAS (eno od vrste genov RAS) in za bolnike s tumorji z mutiranim genom KRAS analizirali ločeno.
Most of the time a single dose is sufficient, but a second dose may be needed.
V večini primerov zadostuje enkratni odmerek, vendar bo morda potreben drugi odmerek.
Most of the time you can still be given Replagal even if these symptoms occur.
Verjetno boste lahko nadaljevali zdravljenje z zdravilom Replagal kljub pojavu teh simptomov.
Most of the time you can still be given VPRIV even if you experience one of these reactions.
Večinoma boste še vedno dobivali zdravilo VPRIV, tudi če imate eno od teh reakcij.
Most of the toxicity showed evidence of reversibility, except for adverse reactions on the male reproductive system and retinal degeneration.
Pri večini toksičnih učinkov je bila opažena reverzibilnost, z izjemo neželenih učinkov na moške reproduktivne organe in degeneracijo mrežnice.
Most of them are mild in nature and reversible.
Večina teh učinkov je blagih in prehodnih:
Most of these adverse reactions were mild to moderate.
Ti neželeni učinki so bili večinoma blagi do zmerni.
Most of these patients had only one positive neutralising sample.
Večina teh bolnikov je imela le en pozitiven nevtralizacijski vzorec.
Most of these patients were adolescent or young adult males.
Večina teh bolnikov je bila mladostnikov ali mladih odraslih moških.
Most of these reactions were noted during the 2 days following the vaccine injection
Večina opisanih neželenih učinkov se je pojavila v 2 dneh po cepljenju.
Most of these side effects occur more frequently in patients with Parkinson’s disease.
Večina teh neželenih učinkov se pojavi pogosteje pri bolnikih s Parkinsonovo boleznijo.
Most of these signs are due to alpha-2- adreno-receptor agonist effects.
Večina teh znakov je posledica agonističnih učinkov na alfa-2- adrenergične-receptorje.
Most patients (60%) reached the 36 mg once a day dosage.
Večina bolnikov (60 %) je na koncu prejemala odmerek 36 mg enkrat na dan.
Most patients (>89%), in both Groups A and B, achieved complete reversal of the anticoagulant effect of dabigatran as measured by dTT or ECT in the first 4 hours after administration of 5 g idarucizumab.
Pri večini bolnikov (> 89 %), tako v skupini A kot B, je prišlo do popolnega izničenja antikoagulacijskega učinka dabigatrana, izmerjenega z dTT ali EKT v prvih 4 urah po dajanju idarucizumaba po 5 g.
Most patients had elevations that were asymptomatic and resolved spontaneously.
Pri večini bolnikov so bila povišanja asimptomatska in so spontano izzvenela.
Most patients had not previously been treated for hepatitis C, though some had genotype 1 infection that was resistant to standard medicines (consisting of either telaprevir or boceprevir – the so-called NS3/4A inhibitors - in combination with peginterferon alfa and ribavirin).
Večina bolnikov se pred tem še ni zdravila zaradi hepatitisa C, nekateri pa so bili okuženi z genotipom 1, ki je bil odporen proti standardnemu zdravljenju (ki sestoji bodisi iz telaprevirja ali boceprevirja – tako imenovanih zaviralcev NS3/4A – v kombinaciji s peginterferonom alfa in ribavirinom).
Most patients had previously received other medicines but needed to change treatment.
Večina bolnikov je pred tem prejemala druga zdravila, a je bilo treba zdravljenje pri njih zamenjati.
Most patients improved after discontinuation of Arava.
Večini bolnikov se je po prenehanju jemanja zdravila Arava stanje izboljšalo.
Most patients improved after discontinuation of Leflunomide Teva.
Pri večini bolnikov se je po prenehanju jemanja zdravila Leflunomid Teva stanje izboljšalo.
Most patients improved after discontinuation of leflunomide.
Večini bolnikov se je po prenehanju jemanja zdravila Leflunomid Winthrop stanje izboljšalo.
Most patients in the clinical trials (> 84%) were Caucasian.
Večina bolnikov v kliničnih preskušanjih (> 84 %) je bila belcev, zato dokončni sklepi o vplivu rase na farmakokinetiko enzalutamida niso mogoči.
Most patients in the study were taking Pradaxa to prevent stroke due to an ‘abnormal heart beat’ (atrial fibrillation).
Večina bolnikov v študiji je zdravilo Pradaxa jemala za preprečevanje možganske kapi zaradi „nenormalnega srčnega utripa“ (atrijske fibrilacije).
Most patients in these three studies were responders to previous on- demand treatment with PDE5 inhibitors.
Večina bolnikov v vseh treh študijah se je odzivala na prejšnje zdravljenje z zaviralci PDE5.
Most patients receiving eltrombopag in combination with peginterferon / ribavirin therapy will experience indirect hyperbilirubinaemia.
Pri večini bolnikov, ki prejema eltrombopag sočasno s peginterferonom / ribavirinom, se bo pojavila indirektna hiperbilirubinemija.
Most patients resumed treatment at a lower dose without recurrence (see section 4.2).
Večina bolnikov je z zdravljenjem nadaljevala z nižjim odmerkom brez ponovnega pojava (glejte poglavje 4.2).
Most patients seroconverted within months of initiation of treatment; although seroconversion in patients under 5 years old with a more severe phenotype occurred mostly within 1 month (mean 26 days versus 45 days in patients 5 years and older).
Pri večini bolnikov se je pojavila serokonverzija v 3 mesecih od začetka zdravljenja; čeprav se je serokonverzija pri bolnikih, mlajših od 5 let, s hujšo obliko fenotipa pojavila predvsem v prvem mesecu (povprečno 26 dni proti 45 dni pri bolnikih, starih 5 let in več).
Most patients taking thalidomide experience side effects.
Pri večini bolnikov, ki jemljejo talidomid, se pojavijo neželeni učinki.
Most patients treated with LEMTRADA in controlled clinical trials in MS experienced mild to moderate IARs during and/or up to 24 hours after LEMTRADA 12 mg administration, which often included headache, rash, pyrexia, nausea, urticaria, pruritus, insomnia, chills, flushing, fatigue, dyspnoea, dysgeusia, chest discomfort, generalised rash, tachycardia, bradycardia, dyspepsia, dizziness, and pain.
Pri večini bolnikov v kliničnih preskušanjih pri MS, zdravljenih z zdravilom LEMTRADA v odmerku 12 mg, so se pojavile blage do zmerne z infuzijo povezane reakcije med in/ali v 24 urah po dajanju zdravila LEMTRADA, ki so pogosto vključevale glavobol, izpuščaj, pireksijo, navzeo, urtikarijo, srbenje, nespečnost, mrazenje, pordevanje, utrujenost, dispnejo, disgevzijo, nelagoden občutek v prsnem košu, generaliziran izpuščaj, tahikardijo, bradikardijo, dispepsijo, omotico in bolečine.
Most patients using Zyclara experience local skin side effects (most commonly redness, scab formation, dryness and shedding of the skin).
Večina bolnikov, ki uporabljajo zdravilo Zyclara, izkusi lokalne neželene učinke na koži (najpogosteje pordelost, tvorbo krast, suhost in luščenje kože).
Most patients using Zyclara for the treatment of AK experience local skin reactions (most frequently erythema, scab, and exfoliation/application site dryness) at the application site.
Večina bolnikov, ki je uporabljala zdravilo Zyclara za zdravljenje AK, je imela lokalne kožne reakcije (najpogosteje eritem, kraste in luščenje/suhost na mestu aplikacije) na mestu nanašanja.
Most patients were successfully treated with the 50-unit/kg dose, with only around 10% of the patients needing a second dose.
Pri večini bolnikov je bilo zdravljenje z odmerkom 50 enot/kg uspešno, le pri približno 10 % bolnikov je bil potreben drugi odmerek.
Most patients were WHO Functional Class II (107/277, 39 %) or III (160/277, 58 %) with a mean baseline 6 minute walking distance of
Večina bolnikov je bila izhodiščno v funkcijskem razredu II (107/277, 39 %) ali III (160/277, 58 %) po razvrstitvi SZO, s povprečno doseženo razdaljo
Most patients were WHO Functional Class II (107/277, 39 %) or III (160/277, 58 %) with a mean baseline 6 minute walking distance of
Večina bolnikov je bila izhodiščno v funkcijskem razredu II (107/277, 39 %) ali III (160/277, 58 %) po razvrstitvi SZO, s povprečno doseženo razdaljo 378 metrov oz.
Most patients who had a response to NeuroBloc by the fourth week had returned to their original condition 12 to 16 weeks after the injection.
Pri večini bolnikov, ki so se do četrtega tedna odzvali na NeuroBloc, je po 12 do 16 tednih po prejeti injekciji prišlo do vrnitve v začetno stanje.
Most patients who received 2 mg of Rapamune 4 hours after ciclosporin had whole blood trough concentrations of sirolimus within the 4 to 12 ng/mL target range (expressed as chromatographic assay values).
Večina bolnikov, ki je prejemala 2 mg zdravila Rapamune 4 ure po ciklosporinu, je imela najnižje koncentracije sirolimusa v stanju dinamičnega ravnovesja v polni krvi znotraj tarčnih meja od 4 do 12 ng/ml (izražene v vrednostih kromatografske metode).
Most patients will experience a reversible red colouration of the skin and membranes lining body cavities (mucous membranes) that may last up to 15 days after administration of Cyanokit.
Pri večini bolnikov se bo pojavilo reverzibilno rdeče obarvanje kože in sluznic, ki lahko traja do 15 dni po uporabi zdravila Cyanokit.
Most patients will experience a reversible red colouration of the skin and mucous membranes that may last up to 15 days after administration of Cyanokit.
Pri večini bolnikov se bo pojavilo reverzibilno rdeče obarvanje kože in sluznic, ki lahko traja do 15 dni po uporabi zdravila Cyanokit.
Most people (very common may affect more than 1 in 10 people) get lower levels of iron in their blood.
Pri večini bolnikov (zelo pogosti - pojavijo se lahko pri več kot 1 od 10 bolnikov) pride do zmanjšanja koncentracij železa v krvi.
Most people are able to empty the capsule with one or two inhalations.
Večina ljudi lahko izprazni kapsulo z enim ali z dvema vdihoma.
Most people will not have come into contact with it and therefore will not have built up protection (‘immunity’) against it.
Večina ljudi z njim ne bo prišla v stik in zato proti njemu ne bo razvila zaščite („imunosti“).
Most reactions are transitory and disappear during continued treatment.
Vecina teh reakcij je prehodnih in med nadaljevanjem zdravljenja izginejo.
Most reactions were of mild-to-moderate grade.
Neželeni učinki so bili večinoma blagi do zmerni.
Most Recent Dose at Onset of First Vascular Occlusive Event
Zadnji odmerek pri začetku prvega vaskularnega okluzivnega dogodka
Most reported symptoms of dyspnoea were mild to moderate in intensity, and most were reported as a single episode early after starting treatment.
Večina opisanih simptomov z dispnejo je bila blagih do zmernih, in večina jih je bila zabeleženih kot enkraten pojav zgodaj po začetku zdravljenja.
Most reports concerned the chin and upper lip, were mild (≥ 90 %), and less than 1 % of all patients withdrew from the studies due to hirsutism.
Največ poročil se je nanašalo na brado in zgornjo ustnico, učinki so bili blagi (≥ 90%), zaradi hirsutizma pa je zdravljenje prekinilo manj kot 1% vseh bolnic.
Most reports of overdose were not associated to adverse events, and severity was mild to moderate.
Večina poročil o prevelikem odmerjanju ni bila povezana z neželenimi učinki, resnost le teh pa je bila blaga do zmerna.
Most responders achieved their MCyR rapidly within 3 months (median 2.8 months) of starting Tasigna treatment and these were sustained.
Večina odzivnih bolnikov je dosegla svoj pomemben citogenetični odziv hitro v prvih 3 mesecih (mediano po 2,8 mesecih) po začetku zdravljenja z zdravilom Tasigna.
Most Serious Side Effects
Najresnejši neželeni učinki
Most serious side effects include mild alterations of blood cell counts (red and white cells, platelets), neurological disorders (disorders that affect the nervous system like hemiparesis [partial paralysis of one side of the body] and thromboembolism (blood clots that may obstruct blood vessels).
Najhujši neželeni učinki vključujejo manjše spremembe v številu krvnih celic (rdeče in bele krvničke, krvne ploščice), nevrološke motnje (motnje, ki vplivajo na živčni sistem, kot so hemipareza [delna paraliza ene strani telesa]) in tromboembolija (nastanek krvnih strdkov, ki lahko zamašijo krvne žile).